CASP8 D302H

CI-VAR-00000471Explore in graph →NP_001219.2:p.Asp302HisNM_001228.4:c.904G>CClinVar 7762 CIViC 650 rs1045485

Curated evidence

Evidence by cancer (1 items)

Grouped by cancer context first, then therapy. The same variant can be sensitizing in one cancer and irrelevant in another — contexts are never merged. 50 items per page; a cancer group may continue on the next page.

civicCuratedShowing 1–1 of 1 evidence items across 1 cancer context on this page · levels, directions and significance as curated at the source; each row links to its CIViC record.

Molecular profile	Therapy	Type	Level	Direction · significance	Rating (1–5)	Status	Evidence	Source
Neuroblastoma1
CASP8 D302H	(prognostic)	Prognostic	B	Supports Poor Outcome	3	accepted	EID1654 21 SNPs were analyzed using qRT-PCR genotyping assays in 500 Neuroblastoma tumor samples, and the CASP8 D302H missense variant was found to be associated with worse overall survival (P = 0.0006; Q = 0… (full text at CIViC) PMID 25502557 · Rihani et al., 2014 · Open in CIViC	civic

ClinVar

Clinical significance (1)

ClinVar interpretations are shown as structured records — significance, review status, star rating, conditions — never flattened into one word.

clinvarCurated1 interpretation · review status and star rating as assigned by ClinVar.

Variation	Clinical significance	Review status	Stars	Conditions	Origin	Submitters	Last evaluated	Source
7762	Benign/Likely benign	criteria provided, multiple submitters, no conflicts	2	BREAST CANCER, PROTECTION AGAINST; Autoimmune lymphoproliferative syndrome type 2B	germline	10	Feb 04, 2026	clinvar